ARTICLE | Emerging Company Profile
Sugar-coated bugs
Centauri aims to take alphamers beyond antibiotic resistance
April 4, 2016 7:00 AM UTC
Centauri Therapeutics Ltd.'s alphamer technology recruits a population of pre-existing, endogenous polyclonal antibodies to kill antibiotic-resistant bacteria.
Centauri acquired the technology from Altermune Technologies LLC, a company founded by PCR inventor Kary Mullis. According to Centauri CEO Mike Westby, Altermune was a virtual company that essentially held the IP of the academic project. "We are now translating what was validated science into generating drugs which will treat antimicrobial-resistant infections," he told BioCentury. ...